Simplifying Global Compliance
FDAnews Drug Daily Bulletin
Genentech Settles Rituxan Case for $20 Million
Dec. 16, 2011
Genentech has agreed to pony up $20 million to the U.S. government to settle a qui tam suit alleging kickbacks for off-label promotion of its cancer drug Rituxan.
Washington Drug Letter
Copyright ©2018. All Rights Reserved.
Design, CMS, Hosting & Web Development :: ePublishing